Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00474851 · ClinicalTrials.gov registry record · Phase 2
The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial
A Phase 2 study of Endometriosis, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT00474851 is a Phase 2 study of Endometriosis that has completed, run by Boston Children's Hospital. The registered enrollment target is 53 participants, below the 263-participant average among 48 other Endometriosis trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00474851, a Phase 2 study of Endometriosis, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether a regimen of norethindrone acetate + placebo or norethindrone acetate + conjugated estrogens is superior in maintaining skeletal health and quality of life in adolescents treated with a GnRH agonist for endometriosis.
Conditions Studied
Interventions
- DRUG Norethindrone acetate + estrogens
- DRUG norethindrone acetate + placebo
Study Locations (1)
Massachusetts
- Children's Hospital Boston - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2007-08 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00474851
The ClinicalTrials.gov registry entry for NCT00474851 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 263-participant average among 48 other Endometriosis trials with a reported enrollment target (80% lower). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometriosis appearing as the primary indexed condition, and to 2 interventions - of which Norethindrone acetate + estrogens is the first listed.
NCT00474851 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00474851 about?
NCT00474851 is a clinical study titled "The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial". The purpose of this study is to determine whether a regimen of norethindrone acetate + placebo or norethindrone acetate + conjugated estrogens is superior in maintaining skeletal health and quality of life in adolescents treated with a GnRH agonist for endometriosis.
What is the current status of trial NCT00474851?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2007-08. Estimated completion is 2015-01.
What conditions does trial NCT00474851 study?
This clinical trial studies the following conditions: Endometriosis.
What interventions are being tested in trial NCT00474851?
The interventions under investigation include: Norethindrone acetate + estrogens (DRUG), norethindrone acetate + placebo (DRUG).
Who is sponsoring clinical trial NCT00474851?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00474851 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometriosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET / MRI
RECRUITING · Phase 2
-
Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis
RECRUITING · Phase 2
-
Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers
RECRUITING · Phase 2
-
Glycemic Regulation as Endometriosis Adjunct Treatment
RECRUITING · Phase 2
-
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
COMPLETED · Phase 2
-
Endometriosis Trial: Study of NBI-56418 in Endometriosis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.